{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39.4"},{"groupId":"OG001","value":"32.0"}]}],"title":"Patients with >=1 evaluable post-baseline mutational analysis"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"}]}],"title":"Patients with any emergent mutation on treatment"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"}]}],"title":"Patients with multiple emergent mutations on treatment"}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"25"}],"units":"Participants"}],"description":"Emerging signs of resistance to nilotinib","groups":[{"description":"Patients resistant or intolerant to either imatinib or dasatinib","id":"OG000","title":"Resistant/i Ntolerant Ph+ CML in CP"},{"description":"Patients newly diagnosed in Chronic phase. Diagnosis within 6 months of date of first cytogenetic analysis confirming Philadelphia chromosome with (9;22) translocation by standard conventional cytogenetic analysis.","id":"OG001","title":"Newly Diagnosed and Untreated Ph+ CML in First CP"}],"paramType":"NUMBER","populationDescription":"Full Analysis Set (FAS): All patients who received at least one dose of study medication","reportingStatus":"POSTED","timeFrame":"up to 66 cycles","title":"Mutational Assessment of BCR-ABL","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}